Last updated on April 17, 2014 at 1:21 EDT

arGEN-X Enters Into a Therapeutic Antibody Alliance With Shire

February 29, 2012

ROTTERDAM, the Netherlands and GHENT, Belgium, February 29, 2012 /PRNewswire/ –

Human Antibody Product Collaboration in Rare Diseases

arGEN-X, a biopharmaceutical company focused on the discovery and development of human
monoclonal antibodies from its proprietary SIMPLE Antibody(TM) platform, announces today
that it has entered into an alliance with Shire to create novel therapeutic antibody
products against multiple targets submitted by Shire.

Using its cutting edge SIMPLE Antibody(TM) discovery technology, arGEN-X will isolate
and characterize human antibodies against the targets that Shire has identified and that
are known to contribute to the pathophysiology of severe, rare genetic diseases. arGEN-X
will also bring its state-of-the-art antibody capabilities to the collaboration for the
preclinical characterization of therapeutic leads. Shire has the option to license the
most promising leads for further preclinical and clinical development and
commercialization worldwide.

Under the terms of the agreement, arGEN-X will receive an upfront technology access
fee, research funding and preclinical success payments. In return for its option to
develop and commercialize products on an exclusive basis, Shire will pay fees, milestones
and royalties on product sales. Specific details of the financial terms were not

Tim Van Hauwermeiren, CEO of arGEN-X, said, “We are delighted to pioneer human
antibodies as novel, first-in-class therapies for rare diseases with a partner of Shire’s
calibre. Shire’s depth of experience in protein-based therapies is the perfect complement
to our own discovery capabilities. We are confident that our SIMPLE Antibody(TM) platform,
which consistently delivers antibodies of therapeutic quality against complex targets
often intractable with other technologies, will bring significant value to this alliance.
We believe this alliance represents an industry first and we are looking forward to an
exciting and productive collaboration with Shire.”

“As a leader in innovative therapies for rare diseases, Shire is continuing to apply
new technologies to address the needs of patients,” said Philip J. Vickers, Senior Vice
President, Research and Development, Shire Human Genetic Therapies (HGT). “Monoclonal
antibody therapy is an underutilized approach to the treatment of rare diseases, and this
novel platform has the potential to bring multiple drug candidates into our early-stage
pipeline. Partnerships such as this one with arGEN-X are an important part of our strategy
to bring new therapies to those suffering from rare diseases worldwide.”

About arGEN-X – http://www.arGEN-X.com

arGEN-X is a preclinical stage biopharmaceutical company that is rapidly leveraging
the power of its broadly applicable, proprietary SIMPLE Antibody(TM) platform to generate
fully human antibodies with differentiated qualities and outstanding therapeutic
potential. The platform excels in delivering large panels of ultra-potent, functionally
diverse antibodies against complex disease targets, especially cell surface receptors and
highly conserved proteins. The superior choice that arGEN-X brings to antibody discovery
enables it to prioritise leads with best-in-class therapeutic properties, thereby
increasing the probability of development success. Antibody leads generated from the
SIMPLE Antibody(TM) platform have outstanding physicochemical properties and consistent
manufacturability, enabling a seamless transition from discovery into development. arGEN-X
has validated its technology on multiple diverse classes of target to date and has
successfully delivered in its collaboration with Eli Lilly & Co..

arGEN-X’ SIMPLE Antibody(TM) platform is based on the active immunization of Camelids
with target antigens to deliver antibody variable regions that are essentially identical
to those of human antibodies. arGEN-X is able to generate full size, human therapeutic
antibodies by combining these variable regions with human constant domains.

The SIMPLE Antibody(TM) platform is covered by broad patent claims, enjoys an
independent, unencumbered patent position and is free of target gatekeeping restrictions.

arGEN-X(TM) and SIMPLE Antibody(TM) are deposited trademarks of arGEN-X BV.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

Shire PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company
that focuses on meeting the needs of the specialist physician. Shire focuses its business
on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal
diseases and regenerative medicine as well as opportunities in other therapeutic areas to
the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition
efforts are focused on products in specialist markets with strong intellectual property
protection and global rights. Shire believes that a carefully selected and balanced
portfolio of products with strategically aligned and relatively small-scale sales forces
will deliver strong results.

For further information on Shire, please visit the Company’s website:


For further information, please contact:

        Citigate Dewe Rogerson                 arGEN-X
        David Dible                            Tim Van Hauwermeiren, MSc, eMBA
        Mark Swallow                           Chief Executive Officer
        Nina Enegren                           T: +31-6-122-85-257
        T: +44-207-282-2949/2948/1050          E: tim.vh@arGEN-X.com
                                               Debbie Allen, Ph.D.
                                               Senior Director, Business Development
                                               T: +44-7974-979479
                                               E: dallen@arGEN-X.com

        Shire - Human Genetic Therapies US     Shire Corporate
        Jessica Cotrone                        Jessica Mann
        T: +1-781-482-9538                     T: +44-1256-894280
        jcotrone@shire.com                     E: jmann@shire.com


Source: PR Newswire